{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:40:33Z","timestamp":1792197633964,"version":"4.4.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10787-026-02396-y","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:42:14Z","timestamp":1789386134000},"page":"6431-6449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Visceral leishmaniasis: an integrated review of resistance mechanisms, host immunometabolism, and next generation therapeutics"],"prefix":"10.1007","volume":"34","author":[{"given":"Krithika","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambak Kumar","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bankuru","family":"Navyatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2396_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229536","volume":"15","author":"JM Abbate","year":"2020","unstructured":"Abbate JM, Maia C, Pereira A et al (2020) Identification of trypanosomatids and blood feeding preferences of phlebotomine sand fly species common in Sicily, Southern Italy. PLoS ONE 15:e0229536. https:\/\/doi.org\/10.1371\/journal.pone.0229536","journal-title":"PLoS ONE"},{"key":"2396_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01943","author":"W Adriaensen","year":"2018","unstructured":"Adriaensen W, Dorlo TPC, Vanham G et al (2018) Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.01943","journal-title":"Front Immunol"},{"key":"2396_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fnano.2021.753947","author":"T Arredondo-Ochoa","year":"2022","unstructured":"Arredondo-Ochoa T, Silva-Mart\u00ednez GA (2022) Microemulsion based nanostructures for drug delivery. Front Nanotechnol. https:\/\/doi.org\/10.3389\/fnano.2021.753947","journal-title":"Front Nanotechnol"},{"key":"2396_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199001043220104","volume":"322","author":"R Badaro","year":"1990","unstructured":"Badaro R, Falcoff E, Badaro FS et al (1990) Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 322:16\u201321. https:\/\/doi.org\/10.1056\/NEJM199001043220104","journal-title":"N Engl J Med"},{"key":"2396_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR (2023) Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther 8:455. https:\/\/doi.org\/10.1038\/s41392-023-01705-z","journal-title":"Signal Transduct Target Ther"},{"key":"2396_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13195756","volume":"13","author":"DE Banegas","year":"2024","unstructured":"Banegas DE, Moioli A, Santoni E et al (2024) Visceral leishmaniasis following A+AVD treatment in a patient with classical Hodgkin\u2019s lymphoma: a case report and review of the literature. J Clin Med 13:5756. https:\/\/doi.org\/10.3390\/jcm13195756","journal-title":"J Clin Med"},{"key":"2396_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006277","volume":"12","author":"M Bangert","year":"2018","unstructured":"Bangert M, Flores-Ch\u00e1vez MD, Llanes-Acevedo IP et al (2018) Validation of rK39 immunochromatographic test and direct agglutination test for the diagnosis of Mediterranean visceral leishmaniasis in Spain. PLoS Negl Trop Dis 12:e0006277. https:\/\/doi.org\/10.1371\/journal.pntd.0006277","journal-title":"PLoS Negl Trop Dis"},{"key":"2396_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.actatropica.2017.08.017","volume":"176","author":"MC Barrera","year":"2017","unstructured":"Barrera MC, Rojas LJ, Weiss A et al (2017) Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility. Acta Trop 176:355\u2013363. https:\/\/doi.org\/10.1016\/j.actatropica.2017.08.017","journal-title":"Acta Trop"},{"key":"2396_CR9","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1016\/j.jacl.2024.04.001","volume":"18","author":"HE Bays","year":"2024","unstructured":"Bays HE, Kirkpatrick CF, Maki KC et al (2024) Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol 18:e320\u2013e350. https:\/\/doi.org\/10.1016\/j.jacl.2024.04.001","journal-title":"J Clin Lipidol"},{"key":"2396_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2478\/host-2023-0009","volume":"17","author":"JL Benchimol","year":"2023","unstructured":"Benchimol JL (2023) The history of new world leishmaniases from a Brazilian perspective. HoST J Hist Sci Technol 17:6\u201335. https:\/\/doi.org\/10.2478\/host-2023-0009","journal-title":"HoST J Hist Sci Technol"},{"key":"2396_CR11","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c09400","author":"K Bharadava","year":"2024","unstructured":"Bharadava K, Upadhyay TK, Kaushal RS et al (2024) Genomic insight of leishmania parasite: in-depth review of drug resistance mechanisms and genetic mutations. ACS Omega. https:\/\/doi.org\/10.1021\/acsomega.3c09400","journal-title":"ACS Omega"},{"key":"2396_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12982-025-00885-z","volume":"22","author":"R Bhattacharya","year":"2025","unstructured":"Bhattacharya R, Bose D, Rodriguez RV et al (2025) A one health plan to combat antimicrobial resistance for improving global health through sustainable development. Discov Public Health 22:521. https:\/\/doi.org\/10.1186\/s12982-025-00885-z","journal-title":"Discov Public Health"},{"key":"2396_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1573618","author":"CK Bhusal","year":"2025","unstructured":"Bhusal CK, Sinha S, Kaur D, Sehgal R (2025) Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies. Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2025.1573618","journal-title":"Front Mol Biosci"},{"key":"2396_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.pt.2024.07.013","volume":"40","author":"C Bogdan","year":"2024","unstructured":"Bogdan C, Islam N-A-K, Barinberg D et al (2024) The immunomicrotope of Leishmania control and persistence. Trends Parasitol 40:788\u2013804. https:\/\/doi.org\/10.1016\/j.pt.2024.07.013","journal-title":"Trends Parasitol"},{"key":"2396_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106883","volume":"107","author":"K Bora","year":"2025","unstructured":"Bora K, Kumar S, Kanaujia SP, Dubey VK (2025) Development and evaluation of novel dual-target drugs encapsulated in liposome against visceral leishmaniasis. J Drug Deliv Sci Technol 107:106883. https:\/\/doi.org\/10.1016\/j.jddst.2025.106883","journal-title":"J Drug Deliv Sci Technol"},{"key":"2396_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/ph19040537","volume":"19","author":"JA Botero-Buitrago","year":"2026","unstructured":"Botero-Buitrago JA, Cardozo-Mu\u00f1oz JC, Cisneros D et al (2026) Kinetoplast-directed therapies: a selective mitochondrial approach to combat leishmaniasis. Pharmaceuticals (Basel) 19:537. https:\/\/doi.org\/10.3390\/ph19040537","journal-title":"Pharmaceuticals (Basel)"},{"key":"2396_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh9902","author":"S Braillard","year":"2023","unstructured":"Braillard S, Keenan M, Breese KJ et al (2023) DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc 1. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.adh9902","journal-title":"Sci Transl Med"},{"key":"2396_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009373","volume":"15","author":"A Casulli","year":"2021","unstructured":"Casulli A (2021) New global targets for NTDs in the WHO roadmap 2021\u20132030. PLoS Negl Trop Dis 15:e0009373. https:\/\/doi.org\/10.1371\/journal.pntd.0009373","journal-title":"PLoS Negl Trop Dis"},{"key":"2396_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-021-05030-8","volume":"14","author":"MA Cavalera","year":"2021","unstructured":"Cavalera MA, Gernone F, Uva A et al (2021) Effect of domperidone (leisguard\u00ae) on antibody titers, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease. Parasit Vectors 14:525. https:\/\/doi.org\/10.1186\/s13071-021-05030-8","journal-title":"Parasit Vectors"},{"key":"2396_CR20","unstructured":"Centers for Disease Control and Prevention (2024) Clinical Testing and Diagnosis for Leishmaniasis. In: Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/leishmaniasis\/hcp\/diagnosis\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/parasites\/leishmaniasis\/health_professionals. Accessed 28 Dec 2025"},{"key":"2396_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/tropicalmed8100457","volume":"8","author":"MR Challapa-Mamani","year":"2023","unstructured":"Challapa-Mamani MR, Tom\u00e1s-Alvarado E, Espinoza-Baigorria A et al (2023) Molecular docking and molecular dynamics simulations in related to Leishmania donovani: an update and literature review. Trop Med Infect Dis 8:457. https:\/\/doi.org\/10.3390\/tropicalmed8100457","journal-title":"Trop Med Infect Dis"},{"key":"2396_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q et al (2023) Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther 8:207. https:\/\/doi.org\/10.1038\/s41392-023-01452-1","journal-title":"Signal Transduct Target Ther"},{"key":"2396_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1320779","author":"D Conde-Torres","year":"2024","unstructured":"Conde-Torres D, Blanco-Gonz\u00e1lez A, Seco-Gonz\u00e1lez A et al (2024) Unraveling lipid and inflammation interplay in cancer, aging and infection for novel theranostic approaches. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1320779","journal-title":"Front Immunol"},{"key":"2396_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2257-4","volume":"17","author":"EDF Daher","year":"2017","unstructured":"Daher EDF, Soares DdeS, Filho SLAP et al (2017) Hyponatremia and risk factors for death in human visceral leishmaniasis: new insights from a cross-sectional study in Brazil. BMC Infect Dis 17:168. https:\/\/doi.org\/10.1186\/s12879-017-2257-4","journal-title":"BMC Infect Dis"},{"key":"2396_CR25","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1128\/JCM.00372-14","volume":"52","author":"CM de Ruiter","year":"2014","unstructured":"de Ruiter CM, van der Veer C, Leeflang MMG et al (2014) Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy. J Clin Microbiol 52:3147\u20133155. https:\/\/doi.org\/10.1128\/JCM.00372-14","journal-title":"J Clin Microbiol"},{"key":"2396_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001514","volume":"6","author":"S Decuypere","year":"2012","unstructured":"Decuypere S, Vanaerschot M, Brunker K et al (2012) Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background. PLoS Negl Trop Dis 6:e1514. https:\/\/doi.org\/10.1371\/journal.pntd.0001514","journal-title":"PLoS Negl Trop Dis"},{"key":"2396_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/14728210903153862","volume":"14","author":"ML den Boer","year":"2009","unstructured":"den Boer ML, Alvar J, Davidson RN et al (2009) Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 14:395\u2013410. https:\/\/doi.org\/10.1517\/14728210903153862","journal-title":"Expert Opin Emerg Drugs"},{"key":"2396_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.4269\/ajtmh.16-0362","volume":"96","author":"E Diro","year":"2017","unstructured":"Diro E, Yansouni CP, Takele Y et al (2017) Diagnosis of visceral leishmaniasis using peripheral blood microscopy in Ethiopia: a prospective phase-III study of the diagnostic performance of different concentration techniques compared to tissue aspiration. Am J Trop Med Hyg 96:190\u2013196. https:\/\/doi.org\/10.4269\/ajtmh.16-0362","journal-title":"Am J Trop Med Hyg"},{"key":"2396_CR29","unstructured":"Dixon J, Khoo S (2023) A phase I double-blind, placebo-controlled (part B only), randomised trial to evaluate the safety, tolerability and pharmacokinetics of single dose in fed state, and repeated doses of DNDI-6899 in healthy participants. In: ISRCTN registry. https:\/\/www.isrctn.com\/ISRCTN31974125. Accessed 7 Jan 2026"},{"key":"2396_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636954","author":"D D\u00f6mer","year":"2021","unstructured":"D\u00f6mer D, Walther T, M\u00f6ller S et al (2021) Neutrophil extracellular traps activate proinflammatory functions of human neutrophils. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.636954","journal-title":"Front Immunol"},{"key":"2396_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijpddr.2020.03.003","volume":"13","author":"N Douanne","year":"2020","unstructured":"Douanne N, Wagner V, Roy G et al (2020) MRPA-independent mechanisms of antimony resistance in Leishmania infantum. Int J Parasitol Drugs Drug Resist 13:28\u201337. https:\/\/doi.org\/10.1016\/j.ijpddr.2020.03.003","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2396_CR32","unstructured":"Drugs for Neglected Diseases (2023) A randomized, open-label, phase II, single-centre study to evaluate the efficacy, safety and pharmacokinetics of LXE408 in patients with primary Visceral Leishmaniasis in Ethiopia. In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05957978. Accessed 7 Jan 2026"},{"key":"2396_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00548-17","author":"F Dumetz","year":"2018","unstructured":"Dumetz F, Cuypers B, Imamura H et al (2018) Molecular preadaptation to antimony resistance in Leishmania donovani on the Indian subcontinent. mSphere. https:\/\/doi.org\/10.1128\/mSphere.00548-17","journal-title":"mSphere"},{"key":"2396_CR34","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1128\/AAC.49.5.1988-1993.2005","volume":"49","author":"K El Fadili","year":"2005","unstructured":"El Fadili K, Messier N, Leprohon P et al (2005) Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother 49:1988\u20131993. https:\/\/doi.org\/10.1128\/AAC.49.5.1988-1993.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2396_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05615-1","volume":"20","author":"BE Feleke","year":"2020","unstructured":"Feleke BE, Feleke TE (2020) Micronutrient levels and their effects on the prognosis of visceral leishmaniasis treatment, a prospective cohort study. BMC Infect Dis 20:867. https:\/\/doi.org\/10.1186\/s12879-020-05615-1","journal-title":"BMC Infect Dis"},{"key":"2396_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","volume":"2","author":"LH Freitas-Junior","year":"2012","unstructured":"Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL (2012) Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it. Int J Parasitol Drugs Drug Resist 2:11\u201319. https:\/\/doi.org\/10.1016\/j.ijpddr.2012.01.003","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2396_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.chom.2013.02.005","volume":"13","author":"J Ghosh","year":"2013","unstructured":"Ghosh J, Bose M, Roy S, Bhattacharyya SN (2013) Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. Cell Host Microbe 13:277\u2013288. https:\/\/doi.org\/10.1016\/j.chom.2013.02.005","journal-title":"Cell Host Microbe"},{"key":"2396_CR38","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3390\/microbiolres15030109","volume":"15","author":"GD Ghouse Peer","year":"2024","unstructured":"Ghouse Peer GD, Priyadarshini A, Gupta A et al (2024) A systematic assessment of Leishmania donovani infection in domestic and wild animal reservoir hosts of zoonotic visceral leishmaniasis in India. Microbiol Res (Pavia) 15:1645\u20131654. https:\/\/doi.org\/10.3390\/microbiolres15030109","journal-title":"Microbiol Res (Pavia)"},{"key":"2396_CR39","doi-asserted-by":"publisher","unstructured":"Ghousepeer GD, Rani M, Kumar A, et al (2026) Insights into drug resistance in Leishmania: mechanisms, therapeutics, and clinical case studies. ADMET DMPK 2992. https:\/\/doi.org\/10.5599\/admet.2992","DOI":"10.5599\/admet.2992"},{"key":"2396_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70328","author":"J Gillon","year":"2025","unstructured":"Gillon J, Delhomme S, Launay D et al (2025) Safety, tolerability and pharmacokinetics of DNDI\u20106148, a novel agent for leishmaniasis: a randomized, controlled, single ascending dose study in healthy participants. Br J Clin Pharmacol. https:\/\/doi.org\/10.1002\/bcp.70328","journal-title":"Br J Clin Pharmacol"},{"key":"2396_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003820","volume":"9","author":"L Gonzalez-Fajardo","year":"2015","unstructured":"Gonzalez-Fajardo L, Fern\u00e1ndez OL, McMahon-Pratt D, Saravia NG (2015) Ex vivo host and parasite response to antileishmanial drugs and immunomodulators. PLoS Negl Trop Dis 9:e0003820. https:\/\/doi.org\/10.1371\/journal.pntd.0003820","journal-title":"PLoS Negl Trop Dis"},{"key":"2396_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41392-024-01745-z","volume":"9","author":"Y Huang","year":"2024","unstructured":"Huang Y, Guo X, Wu Y et al (2024) Nanotechnology\u2019s frontier in combatting infectious and inflammatory diseases: prevention and treatment. Signal Transduct Target Ther 9:34. https:\/\/doi.org\/10.1038\/s41392-024-01745-z","journal-title":"Signal Transduct Target Ther"},{"key":"2396_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pt.2019.10.005","volume":"36","author":"AV Ibarra-Meneses","year":"2020","unstructured":"Ibarra-Meneses AV, Moreno J, Carrillo E (2020) New strategies and biomarkers for the control of visceral leishmaniasis. Trends Parasitol 36:29\u201338. https:\/\/doi.org\/10.1016\/j.pt.2019.10.005","journal-title":"Trends Parasitol"},{"key":"2396_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01398-5","volume":"22","author":"MJ Iqbal","year":"2024","unstructured":"Iqbal MJ, Kabeer A, Abbas Z et al (2024) Interplay of oxidative stress, cellular communication and signaling pathways in cancer. Cell Commun Signal 22:7. https:\/\/doi.org\/10.1186\/s12964-023-01398-5","journal-title":"Cell Commun Signal"},{"key":"2396_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.1112680","volume":"309","author":"AC Ivens","year":"2005","unstructured":"Ivens AC, Peacock CS, Worthey EA et al (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309:436\u2013442. https:\/\/doi.org\/10.1126\/science.1112680","journal-title":"Science"},{"key":"2396_CR46","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.4269\/ajtmh.2005.73.1005","volume":"73","author":"TK Jha","year":"2005","unstructured":"Jha TK, Sundar S, Thakur CP et al (2005) A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 73:1005\u20131011. https:\/\/doi.org\/10.4269\/ajtmh.2005.73.1005","journal-title":"Am J Trop Med Hyg"},{"key":"2396_CR47","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.7150\/ijbs.92274","volume":"20","author":"W Jiang","year":"2024","unstructured":"Jiang W, Jin W-L, Xu A-M (2024) Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities. Int J Biol Sci 20:2044\u20132071. https:\/\/doi.org\/10.7150\/ijbs.92274","journal-title":"Int J Biol Sci"},{"key":"2396_CR48","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.vaccine.2023.01.057","volume":"41","author":"PM Kaye","year":"2023","unstructured":"Kaye PM, Matlashewski G, Mohan S et al (2023) Vaccine value profile for leishmaniasis. Vaccine 41:S153\u2013S175. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.057","journal-title":"Vaccine"},{"key":"2396_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01492","author":"R Kumar","year":"2017","unstructured":"Kumar R, Chauhan SB, Ng SS et al (2017) Immune checkpoint targets for host-directed therapy to prevent and treat leishmaniasis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.01492","journal-title":"Front Immunol"},{"key":"2396_CR50","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1016\/j.celrep.2020.01.099","volume":"30","author":"R Kumar","year":"2020","unstructured":"Kumar R, Bunn PT, Singh SS et al (2020) Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis. Cell Rep 30:2512-2525.e9. https:\/\/doi.org\/10.1016\/j.celrep.2020.01.099","journal-title":"Cell Rep"},{"key":"2396_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101179","volume":"12","author":"A Lafleur","year":"2024","unstructured":"Lafleur A, Daffis S, Mowbray C, Arana B (2024) Immunotherapeutic strategies as potential treatment options for cutaneous leishmaniasis. Vaccines 12:1179. https:\/\/doi.org\/10.3390\/vaccines12101179","journal-title":"Vaccines"},{"key":"2396_CR52","doi-asserted-by":"publisher","first-page":"26301","DOI":"10.1074\/jbc.M102351200","volume":"276","author":"D L\u00e9gar\u00e9","year":"2001","unstructured":"L\u00e9gar\u00e9 D, Richard D, Mukhopadhyay R et al (2001) The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem 276:26301\u201326307. https:\/\/doi.org\/10.1074\/jbc.M102351200","journal-title":"J Biol Chem"},{"key":"2396_CR53","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1128\/EC.00152-06","volume":"5","author":"P Leprohon","year":"2006","unstructured":"Leprohon P, L\u00e9gar\u00e9 D, Girard I et al (2006) Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryot Cell 5:1713\u20131725. https:\/\/doi.org\/10.1128\/EC.00152-06","journal-title":"Eukaryot Cell"},{"key":"2396_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12090802","volume":"12","author":"M Lesani","year":"2022","unstructured":"Lesani M, Gosmanov C, Paun A et al (2022) Impact of visceral leishmaniasis on local organ metabolism in hamsters. Metabolites 12:802. https:\/\/doi.org\/10.3390\/metabo12090802","journal-title":"Metabolites"},{"key":"2396_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003136","volume":"8","author":"JA Lindoso","year":"2014","unstructured":"Lindoso JA, Cota GF, da Cruz AM et al (2014) Visceral leishmaniasis and HIV coinfection in Latin America. PLoS Negl Trop Dis 8:e3136. https:\/\/doi.org\/10.1371\/journal.pntd.0003136","journal-title":"PLoS Negl Trop Dis"},{"key":"2396_CR56","doi-asserted-by":"crossref","unstructured":"Loglo A, Aniagyei W, Vivekanandan MM, et al (2024) A systematic review and meta-analysis of the association between neglected tropical diseases and malnutrition: more research needed on diseases other than intestinal parasites, leishmaniasis and leprosy","DOI":"10.1099\/acmi.0.000800.v2"},{"key":"2396_CR57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1051\/parasite\/2011182115","volume":"18","author":"PM Loiseau","year":"2011","unstructured":"Loiseau PM, Cojean S, Schr\u00e9vel J (2011) Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite 18:115\u2013119. https:\/\/doi.org\/10.1051\/parasite\/2011182115","journal-title":"Parasite"},{"key":"2396_CR58","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1084\/jem.20171576","volume":"215","author":"X Ma","year":"2018","unstructured":"Ma X, Bi E, Huang C et al (2018) Cholesterol negatively regulates IL-9\u2013producing CD8+ T cell differentiation and antitumor activity. J Exp Med 215:1555\u20131569. https:\/\/doi.org\/10.1084\/jem.20171576","journal-title":"J Exp Med"},{"key":"2396_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010718","volume":"16","author":"R Mahajan","year":"2022","unstructured":"Mahajan R, Owen SI, Kumar S et al (2022) Prevalence and determinants of asymptomatic Leishmania infection in HIV-infected individuals living within visceral leishmaniasis endemic areas of Bihar, India. PLoS Negl Trop Dis 16:e0010718. https:\/\/doi.org\/10.1371\/journal.pntd.0010718","journal-title":"PLoS Negl Trop Dis"},{"key":"2396_CR60","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/jac\/dkp468","volume":"65","author":"S Mandal","year":"2010","unstructured":"Mandal S, Maharjan M, Singh S et al (2010) Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India. J Antimicrob Chemother 65:496\u2013507. https:\/\/doi.org\/10.1093\/jac\/dkp468","journal-title":"J Antimicrob Chemother"},{"key":"2396_CR61","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2174\/1389450121666200422083735","volume":"21","author":"R Mansuri","year":"2020","unstructured":"Mansuri R, Singh J, Diwan A (2020) An insight into the current perspective and potential drug targets for visceral leishmaniasis (VL). Curr Drug Targets 21:1105\u20131129. https:\/\/doi.org\/10.2174\/1389450121666200422083735","journal-title":"Curr Drug Targets"},{"key":"2396_CR62","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/j.1365-2958.2005.04782.x","volume":"57","author":"N Marquis","year":"2005","unstructured":"Marquis N, Gourbal B, Rosen BP et al (2005) Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol 57:1690\u20131699. https:\/\/doi.org\/10.1111\/j.1365-2958.2005.04782.x","journal-title":"Mol Microbiol"},{"key":"2396_CR63","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1128\/JCM.01733-09","volume":"48","author":"R Maurya","year":"2010","unstructured":"Maurya R, Mehrotra S, Prajapati VK et al (2010) Evaluation of blood agar microtiter plates for culturing Leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J Clin Microbiol 48:1932\u20131934. https:\/\/doi.org\/10.1128\/JCM.01733-09","journal-title":"J Clin Microbiol"},{"key":"2396_CR64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4269\/ajtmh.2007.77.89","volume":"77","author":"Y Melaku","year":"2007","unstructured":"Melaku Y, Collin SM, Keus K et al (2007) Treatment of Kala-Azar in Southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 77:89\u201394. https:\/\/doi.org\/10.4269\/ajtmh.2007.77.89","journal-title":"Am J Trop Med Hyg"},{"key":"2396_CR65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/2229-5070.129142","volume":"4","author":"S Mohapatra","year":"2014","unstructured":"Mohapatra S (2014) Drug resistance in leishmaniasis: newer developments. Trop Parasitol 4:4. https:\/\/doi.org\/10.4103\/2229-5070.129142","journal-title":"Trop Parasitol"},{"key":"2396_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1414493","author":"J Na","year":"2024","unstructured":"Na J, Engwerda C (2024) The role of CD4+ T cells in visceral leishmaniasis; new and emerging roles for NKG7 and TGF\u03b2. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2024.1414493","journal-title":"Front Cell Infect Microbiol"},{"key":"2396_CR67","doi-asserted-by":"publisher","first-page":"11305","DOI":"10.1021\/cr500365f","volume":"114","author":"AS Nagle","year":"2014","unstructured":"Nagle AS, Khare S, Kumar AB et al (2014) Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chem Rev 114:11305\u201311347. https:\/\/doi.org\/10.1021\/cr500365f","journal-title":"Chem Rev"},{"key":"2396_CR68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.tips.2009.11.005","volume":"31","author":"PN Newton","year":"2010","unstructured":"Newton PN, Green MD, Fern\u00e1ndez FM (2010) Impact of poor-quality medicines in the \u2018developing\u2019 world. Trends Pharmacol Sci 31:99\u2013101. https:\/\/doi.org\/10.1016\/j.tips.2009.11.005","journal-title":"Trends Pharmacol Sci"},{"key":"2396_CR69","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.4314\/tjpr.v24i9.12","volume":"24","author":"EC Oranu","year":"2025","unstructured":"Oranu EC, Ozoh MI, Madueke JA et al (2025) The role of gut microbiota in modulating immune responses to neglected tropical diseases: a new frontier in host-pathogen interactions. Trop J Pharm Res 24:1193\u20131202. https:\/\/doi.org\/10.4314\/tjpr.v24i9.12","journal-title":"Trop J Pharm Res"},{"key":"2396_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00663-w","volume":"11","author":"M Pareyn","year":"2025","unstructured":"Pareyn M, Alves F, Burza S et al (2025) Leishmaniasis. Nat Rev Dis Primers 11:81. https:\/\/doi.org\/10.1038\/s41572-025-00663-w","journal-title":"Nat Rev Dis Primers"},{"key":"2396_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69276-5","volume":"10","author":"S Parvez","year":"2020","unstructured":"Parvez S, Yadagiri G, Gedda MR et al (2020) Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Rep 10:12243. https:\/\/doi.org\/10.1038\/s41598-020-69276-5","journal-title":"Sci Rep"},{"key":"2396_CR72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3329\/jom.v26i2.84360","volume":"26","author":"S Paul","year":"2025","unstructured":"Paul S, Basher A, Aftab KA et al (2025) Relapse Kala-azar: a potential threat to sustaining public health elimination in Bangladesh and ways to overcome it. J Med 26:131\u2013141. https:\/\/doi.org\/10.3329\/jom.v26i2.84360","journal-title":"J Med"},{"key":"2396_CR73","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S1473-3099(24)00488-2","volume":"24","author":"C Petersen","year":"2024","unstructured":"Petersen C (2024) A model of vector-targeted interventions for visceral leishmaniasis. Lancet Infect Dis 24:1187\u20131188. https:\/\/doi.org\/10.1016\/S1473-3099(24)00488-2","journal-title":"Lancet Infect Dis"},{"key":"2396_CR74","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1093\/jac\/dkab226","volume":"76","author":"S Pomel","year":"2021","unstructured":"Pomel S, Cojean S, Pons V et al (2021) An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis. J Antimicrob Chemother 76:2640\u20132650. https:\/\/doi.org\/10.1093\/jac\/dkab226","journal-title":"J Antimicrob Chemother"},{"key":"2396_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006052","volume":"11","author":"A Ponte-Sucre","year":"2017","unstructured":"Ponte-Sucre A, Gamarro F, Dujardin J-C et al (2017) Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis 11:e0006052. https:\/\/doi.org\/10.1371\/journal.pntd.0006052","journal-title":"PLoS Negl Trop Dis"},{"key":"2396_CR76","volume-title":"The evolution in pharmacology of infectious diseases: 2022","year":"2024","unstructured":"Porta EOJ, Saffaei A, Kalesh K (eds) (2024) The evolution in pharmacology of infectious diseases: 2022. Frontiers Media SA"},{"key":"2396_CR77","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s12026-022-09292-x","volume":"70","author":"S Prakash","year":"2022","unstructured":"Prakash S, Kumar Rai A (2022) Retinoic acid increases the cellular cholesterol predominantly in a mTOR-independent manner. Immunol Res 70:530\u2013536. https:\/\/doi.org\/10.1007\/s12026-022-09292-x","journal-title":"Immunol Res"},{"key":"2396_CR78","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02699-22","author":"S Prakash","year":"2022","unstructured":"Prakash S, Rai AK (2022) Retinoic acid increases cellular cholesterol in leishmania donovani-infected macrophages in an mTOR-independent manner. Microbiol Spectr. https:\/\/doi.org\/10.1128\/spectrum.02699-22","journal-title":"Microbiol Spectr"},{"key":"2396_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-981-19-8225-5_2","volume-title":"Pathobiology of parasitic protozoa: dynamics and dimensions","author":"S Prakash","year":"2023","unstructured":"Prakash S, Rai AK (2023a) Intertwining of retinoic acid and cholesterol pathway and its consequences in Leishmania donovani-infected macrophages. Pathobiology of parasitic protozoa: dynamics and dimensions. Springer Nature Singapore, Singapore, pp 19\u201343"},{"key":"2396_CR80","doi-asserted-by":"publisher","first-page":"14473","DOI":"10.1080\/07391102.2023.2193983","volume":"41","author":"S Prakash","year":"2023","unstructured":"Prakash S, Rai AK (2023b) Retinoic acid shows direct parasiticidal activity by targeting ergosterol pathway in Leishmania donovani: a potential therapeutic advancement. J Biomol Struct Dyn 41:14473\u201314483. https:\/\/doi.org\/10.1080\/07391102.2023.2193983","journal-title":"J Biomol Struct Dyn"},{"key":"2396_CR81","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biochi.2022.03.002","volume":"198","author":"S Prakash","year":"2022","unstructured":"Prakash S, Saini S, Kumari S et al (2022) Retinoic acid restores the levels of cellular cholesterol in Leishmania donovani infected macrophages by increasing npc1 and npc2 expressions. Biochimie 198:23\u201332. https:\/\/doi.org\/10.1016\/j.biochi.2022.03.002","journal-title":"Biochimie"},{"key":"2396_CR82","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.molbiopara.2003.10.002","volume":"133","author":"TJ Pucadyil","year":"2004","unstructured":"Pucadyil TJ, Tewary P, Madhubala R, Chattopadhyay A (2004) Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol Biochem Parasitol 133:145\u2013152. https:\/\/doi.org\/10.1016\/j.molbiopara.2003.10.002","journal-title":"Mol Biochem Parasitol"},{"key":"2396_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074862","volume":"8","author":"S Rai","year":"2013","unstructured":"Rai S, Bhaskar GSK et al (2013) Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS ONE 8:e74862. https:\/\/doi.org\/10.1371\/journal.pone.0074862","journal-title":"PLoS ONE"},{"key":"2396_CR84","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2174\/1389557511313050010","volume":"13","author":"KA Reynolds","year":"2013","unstructured":"Reynolds KA, Loughlin WA, Young DJ (2013) Quinolines as chemotherapeutic agents for leishmaniasis. Mini-Rev Med Chem 13:730\u2013743. https:\/\/doi.org\/10.2174\/1389557511313050010","journal-title":"Mini-Rev Med Chem"},{"key":"2396_CR85","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/cid\/cit102","volume":"56","author":"S Rijal","year":"2013","unstructured":"Rijal S, Ostyn B, Uranw S et al (2013) Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56:1530\u20131538. https:\/\/doi.org\/10.1093\/cid\/cit102","journal-title":"Clin Infect Dis"},{"key":"2396_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004710","volume":"10","author":"K Roy","year":"2016","unstructured":"Roy K, Mandloi S, Chakrabarti S, Roy S (2016) Cholesterol corrects altered conformation of MHC-II protein in Leishmania donovani infected macrophages: implication in therapy. PLoS Negl Trop Dis 10:e0004710. https:\/\/doi.org\/10.1371\/journal.pntd.0004710","journal-title":"PLoS Negl Trop Dis"},{"key":"2396_CR87","first-page":"16","volume":"45","author":"J Roychoudhury","year":"2008","unstructured":"Roychoudhury J, Ali N (2008) Sodium stibogluconate: therapeutic use in the management of leishmaniasis. Indian J Biochem Biophys 45:16\u201322","journal-title":"Indian J Biochem Biophys"},{"key":"2396_CR88","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/iub.1759","volume":"70","author":"A Saha","year":"2018","unstructured":"Saha A, Basu M, Ukil A (2018) Recent advances in understanding Leishmania donovani infection: the importance of diverse host regulatory pathways. IUBMB Life 70:593\u2013601. https:\/\/doi.org\/10.1002\/iub.1759","journal-title":"IUBMB Life"},{"key":"2396_CR89","doi-asserted-by":"publisher","DOI":"10.3201\/eid2608.200557","author":"P Saini","year":"2020","unstructured":"Saini P, Kumar NP, Ajithlal PM et al (2020) Visceral Leishmaniasis caused by Leishmania donovani Zymodeme MON-37, Western Ghats, India. Emerg Infect Dis. https:\/\/doi.org\/10.3201\/eid2608.200557","journal-title":"Emerg Infect Dis"},{"key":"2396_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030330","volume":"16","author":"PO Sakyi","year":"2023","unstructured":"Sakyi PO, Kwofie SK, Tuekpe JK et al (2023) Inhibiting Leishmania donovani sterol methyltransferase to identify lead compounds using molecular modelling. Pharmaceuticals (Basel) 16:330. https:\/\/doi.org\/10.3390\/ph16030330","journal-title":"Pharmaceuticals (Basel)"},{"key":"2396_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.624009","author":"M Samant","year":"2021","unstructured":"Samant M, Sahu U, Pandey SC, Khare P (2021) Role of cytokines in experimental and human visceral leishmaniasis. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2021.624009","journal-title":"Front Cell Infect Microbiol"},{"key":"2396_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.00375","author":"MF Santos","year":"2020","unstructured":"Santos MF, Alexandre-Pires G, Pereira MA et al (2020) Immunophenotyping of peripheral blood, lymph node, and bone marrow T lymphocytes during canine leishmaniosis and the impact of antileishmanial chemotherapy. Front Vet Sci. https:\/\/doi.org\/10.3389\/fvets.2020.00375","journal-title":"Front Vet Sci"},{"key":"2396_CR93","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/1874104501105010031","volume":"05","author":"K Seifert","year":"2011","unstructured":"Seifert K (2011) Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med Chem J 05:31\u201339. https:\/\/doi.org\/10.2174\/1874104501105010031","journal-title":"Open Med Chem J"},{"key":"2396_CR94","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01057-20","author":"G Semini","year":"2020","unstructured":"Semini G, Paape D, Blume M et al (2020) Leishmania encodes a bacterium-like 2,4-dienoyl-coenzyme A reductase that is required for fatty acid \u03b2-oxidation and intracellular parasite survival. Mbio. https:\/\/doi.org\/10.1128\/mBio.01057-20","journal-title":"Mbio"},{"key":"2396_CR95","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.actatropica.2011.05.017","volume":"119","author":"N Shakya","year":"2011","unstructured":"Shakya N, Sane SA, Vishwakarma P et al (2011) Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator\u2014Picroliv. Acta Trop 119:188\u2013193. https:\/\/doi.org\/10.1016\/j.actatropica.2011.05.017","journal-title":"Acta Trop"},{"key":"2396_CR96","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s13071-014-0596-1","volume":"7","author":"N Singh","year":"2014","unstructured":"Singh N, Chatterjee M, Sundar S (2014) The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India. Parasit Vectors 7:596. https:\/\/doi.org\/10.1186\/s13071-014-0596-1","journal-title":"Parasit Vectors"},{"key":"2396_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13123008","volume":"13","author":"RMde Souza","year":"2025","unstructured":"Souza RMde, Tuon FF, Lindoso JAL et al (2025) Cutaneous and mucocutaneous leishmaniasis: perspectives on immunity, virulence, and treatment. Biomedicines 13:3008. https:\/\/doi.org\/10.3390\/biomedicines13123008","journal-title":"Biomedicines"},{"key":"2396_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trstmh.2010.09.006","volume":"105","author":"P Srivastava","year":"2011","unstructured":"Srivastava P, Dayama A, Mehrotra S, Sundar S (2011) Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg 105:1\u20136. https:\/\/doi.org\/10.1016\/j.trstmh.2010.09.006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2396_CR99","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1042\/CS20220531","volume":"137","author":"Z Strizova","year":"2023","unstructured":"Strizova Z, Benesova I, Bartolini R et al (2023) M1\/M2 macrophages and their overlaps \u2013 myth or reality? Clin Sci 137:1067\u20131093. https:\/\/doi.org\/10.1042\/CS20220531","journal-title":"Clin Sci"},{"key":"2396_CR100","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","volume":"6","author":"S Sundar","year":"2001","unstructured":"Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6:849\u2013854. https:\/\/doi.org\/10.1046\/j.1365-3156.2001.00778.x","journal-title":"Trop Med Int Health"},{"key":"2396_CR101","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1128\/CDLI.9.5.951-958.2002","volume":"9","author":"S Sundar","year":"2002","unstructured":"Sundar S, Rai M (2002) Laboratory diagnosis of visceral leishmaniasis. Clin Vaccine Immunol 9:951\u2013958. https:\/\/doi.org\/10.1128\/CDLI.9.5.951-958.2002","journal-title":"Clin Vaccine Immunol"},{"key":"2396_CR102","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1517\/14656566.6.16.2821","volume":"6","author":"S Sundar","year":"2005","unstructured":"Sundar S, Rai M (2005) Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6:2821\u20132829. https:\/\/doi.org\/10.1517\/14656566.6.16.2821","journal-title":"Expert Opin Pharmacother"},{"key":"2396_CR103","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.trstmh.2005.08.018","volume":"100","author":"S Sundar","year":"2006","unstructured":"Sundar S, Singh RK, Maurya R et al (2006) Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans R Soc Trop Med Hyg 100:533\u2013537. https:\/\/doi.org\/10.1016\/j.trstmh.2005.08.018","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2396_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-023-05939-2","volume":"16","author":"A Tabbabi","year":"2023","unstructured":"Tabbabi A, Mizushima D, Yamamoto DS, Kato H (2023) Effects of host species on microbiota composition in Phlebotomus and Lutzomyia sand flies. Parasit Vectors 16:310. https:\/\/doi.org\/10.1186\/s13071-023-05939-2","journal-title":"Parasit Vectors"},{"key":"2396_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012382","volume":"20","author":"LB Tulloch","year":"2024","unstructured":"Tulloch LB, Tinti M, Wall RJ et al (2024) Sterol 14-alpha demethylase (CYP51) activity in Leishmania donovani is likely dependent upon cytochrome P450 reductase 1. PLoS Pathog 20:e1012382. https:\/\/doi.org\/10.1371\/journal.ppat.1012382","journal-title":"PLoS Pathog"},{"key":"2396_CR106","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/pathogens15020176","volume":"15","author":"CE Ugwu","year":"2026","unstructured":"Ugwu CE, Akinsulie OC, Ayandokun TF et al (2026) Mechanisms and therapeutic potential of nutritional immunity. Pathogens 15:176. https:\/\/doi.org\/10.3390\/pathogens15020176","journal-title":"Pathogens"},{"key":"2396_CR107","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.idc.2018.10.005","volume":"33","author":"J van Griensven","year":"2019","unstructured":"van Griensven J, Diro E (2019) Visceral leishmaniasis. Infect Dis Clin North Am 33:79\u201399. https:\/\/doi.org\/10.1016\/j.idc.2018.10.005","journal-title":"Infect Dis Clin North Am"},{"key":"2396_CR108","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1016\/S1473-3099(23)00353-5","volume":"24","author":"J van Griensven","year":"2024","unstructured":"van Griensven J, Dorlo TP, Diro E et al (2024) The status of combination therapy for visceral leishmaniasis: an updated review. Lancet Infect Dis 24:e36\u2013e46. https:\/\/doi.org\/10.1016\/S1473-3099(23)00353-5","journal-title":"Lancet Infect Dis"},{"key":"2396_CR109","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1586\/14787210.2014.916614","volume":"12","author":"M Vanaerschot","year":"2014","unstructured":"Vanaerschot M, Dumetz F, Roy S et al (2014) Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? Expert Rev Anti Infect Ther 12:937\u2013946. https:\/\/doi.org\/10.1586\/14787210.2014.916614","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2396_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2318-8","volume":"17","author":"S Verma","year":"2017","unstructured":"Verma S, Singh R, Sharma V et al (2017) Development of a rapid loop-mediated isothermal amplification assay for diagnosis and assessment of cure of Leishmania infection. BMC Infect Dis 17:223. https:\/\/doi.org\/10.1186\/s12879-017-2318-8","journal-title":"BMC Infect Dis"},{"key":"2396_CR111","volume-title":"Optimizing visceral leishmaniasis treatment in Eastern Africa","author":"L Verrest","year":"2023","unstructured":"Verrest L (2023) Optimizing visceral leishmaniasis treatment in Eastern Africa. Utrecht University"},{"key":"2396_CR112","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.immuni.2016.12.006","volume":"45","author":"SB Widenmaier","year":"2016","unstructured":"Widenmaier SB, Hotam\u0131\u015fl\u0131gil GS (2016) Immune cell intolerance for excess cholesterol. Immunity 45:1186\u20131188. https:\/\/doi.org\/10.1016\/j.immuni.2016.12.006","journal-title":"Immunity"},{"key":"2396_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fitd.2022.837460","author":"G-J Wijnant","year":"2022","unstructured":"Wijnant G-J, Dumetz F, Dirkx L et al (2022) Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis. Frontiers in Tropical Diseases. https:\/\/doi.org\/10.3389\/fitd.2022.837460","journal-title":"Frontiers in Tropical Diseases"},{"key":"2396_CR114","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.micpath.2004.11.002","volume":"38","author":"ME Wilson","year":"2005","unstructured":"Wilson ME, Jeronimo SMB, Pearson RD (2005) Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38:147\u2013160. https:\/\/doi.org\/10.1016\/j.micpath.2004.11.002","journal-title":"Microb Pathog"},{"key":"2396_CR115","unstructured":"World Health Organization (2025) Leishmaniasis. In: World Health Organization. https:\/\/www.who.int\/india\/health-topics\/leishmaniasis. Accessed 28 Dec 2025"},{"key":"2396_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1096458","author":"G Yadagiri","year":"2023","unstructured":"Yadagiri G, Singh A, Arora K, Mudavath SL (2023) Immunotherapy and immunochemotherapy in combating visceral leishmaniasis. Front Med (Lausanne). https:\/\/doi.org\/10.3389\/fmed.2023.1096458","journal-title":"Front Med (Lausanne)"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02396-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02396-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02396-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:17Z","timestamp":1792194917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02396-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2396"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02396-y","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"11 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}